A CT scan of the chest, abdomen, and pelvis did not reveal lymphadenopathy or hepatomegaly
These are the newer GLP-1 therapies that have shown superior results to prior therapies in lowering A1C (blood sugar) levels of diabetics and helping those who are obese lose weight
286, R13
Moreover, peptide analogues that are unimolecular co-agonists of both GLP-1R and GCGR are currently in clinical development for the treatment of T2D, obesity and non-alcoholic steatohepatitis (NASH) 2,3,5,6,7
Care With Guardrails at AgeRejuvenation AgeRejuvenation is built around root-cause evaluation, not isolated symptom management
Throughout this guide, the protocol recommendations draw from Phase 2 clinical trial data published in the New England Journal of Medicine, nutritional analysis from trial participants, and practical considerations specific to the Canadian market where research peptides represent the primary access pathway